Bacterial vaginosis (BV) drugs market is anticipated to grow at a significant CAGR during the forecast period. The rising incidence of bacterial vaginosis among women across the globe coupled with the surging demand for OTC products is augmenting the growth of the market. It is a vaginal disorder that produces vaginal discharge on account of an overgrowth of certain kinds of bacteria in the vagina. BV is a global concern due to the increased risk of the acquisition of sexually transmitted infections. BV can occur in any age group, however, globally it is more prevalent in females of reproductive age.
According to the American Sexual Health Association 2019, BV is a common gynecologic infection, which affects nearly 29% of women in the US. At least 15% of the sexually active population are suffering from BV; due to this BV is three-four times more common than urinary tract infections (UTI). Hence, the rising incidence of BV is leading to an upsurge in R&D for its treatment by private manufacturers and research organizations. However, several clinical trials are undergoing to enlarge the potential future of bacterial vaginosis drugs.
Key players of the market include Bayer AG, Pfizer Inc., and Sanofi S.A., among others. The market players are eyeing to strengthen their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in August 2020, Daré Bioscience, Inc., one of the prominent leaders in women’s health innovation, announced the publication of a proof of concept study of DARE-BV1 in Clinical and Experimental Obstetrics & Gynecology, an international journal focused on the publication of high-quality scientific research related to obstetrics and gynaecology and women’s health. DARE-BV1 is a novel thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% that is being evaluated as a one-time vaginally administered treatment for bacterial vaginosis (BV).
To Request a Sample of our Report on Bacterial Vaginosis Drugs Market: https://www.omrglobal.com/request-sample/bacterial-vaginosis-drugs-market
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
- Segment Covered
- Regions Covered- Globally
- Competitive Landscape: Bayer AG, Pfizer Inc., and Sanofi S.A., among others.
Bacterial Vaginosis Drugs Market by Segmentation
By Type
- Rx
- OTC
By Application
- Hospital
- Pharmacy
- Others
A full Report of Bacterial Vaginosis Drugs Market is Available at: https://www.omrglobal.com/industry-reports/bacterial-vaginosis-drugs-market
Bacterial Vaginosis Drugs Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
